Khan, Michael - University of Warwick - Department of Biomedical Science

个人简介

Executive Director Silence Therapeutics PLC 2013-present, CMO from 2012-2014, Head of Translational Medicine 2015-present: 3 years of board-level experience in Industry. Head hunted to join this RNAi therapeutics company, initially as an NED and advisor in 2012 and invited to become CMO and Executive Director later that year. Formulated company strategy for R and D, planning and initiating preclinical and translational projects. Managing relationships with CROs and academic collaborators. Active across many thematic areas of drug development from preclinical through regulatory and planning, initiation and running of Clinical Trials. Contributed to three successful fund-raising efforts and took part in all road-shows/funder presentations, raising over £80,000,000 since 2013. Invited speaker at several industry events/conferences. Have been the public face of the company at conferences. Over 30 years of clinical experience, including 17 years as a senior NHS consultant physician and clinical academic, in general medicine, diabetes and endocrinology: Run county coronary prevention and diabetes clinical services. General medical take and in-patient care. Strong track record in service development, research and high-level senior management both in the NHS and University. Have held numerous senior roles at national and international level, including with the EC and NICE. Much of this past expertise and experience is directly relevant to translational research, decision making and strategic planning in industry. Given, the emphasis on partnerships between academia and industry now in drug development, my experience of both sectors at high-level will be very useful. Maintained Clinical and research position at 1 day a week. This was deemed to be advantageous for Silence Therapeutics PLC and was accepted by UHCW and University of Warwick for the same reasons, namely helping to build academic-private sector partnerships. Has facilitated development of new clinical trials in HNSCC, a preclinical programme in preeclampsia and a drug delivery programme for ODN using conjugation chemistry. Other Relevant experience Expert advisor to NICE. Expert advisor and panel member Clinical Guidelines Development Group (CGDG) and NICE for Cardiovascular risk and lipid-lowering drugs 2012-2014. Made a substantial contribution, over 2 years, to developing and writing the new NICE guideline (CG181) on Lipid-lowering drugs and assessment of cardiovascular risk. Overall extended access to statins to over 5 million more adults in England by reducing the risk threshold for intervention from 20% to a 10% predicted risk of CVD over 10 years. Highly cited researcher, over 100 publications across basic science and clinical medicine including in Cell, Nature, BMJ and Lancet. Just under 3000 citations, H-factor 18. Published the second edition of the popular Molecular Biology of Cancer- Willey-Blackwell. Grants and awards, 2 active grants and over 2 million pounds funding from BBSRC and QNRF, looking at pregnancy-associated diabetes and colon cancer biomarkers respectively. Elected to FRCS and Association of Physicians. EC advisor. 2002- present. Senior administrative roles. Head of Molecular Medicine at University of Warwick from 2002-2006 (completed 5 year period). Member of Senior Management group for Department of Biological Sciences, 2002-2006. One of the pioneers of Warwick Systems Biology. Chair of the exam boards for Cardiovascular risk and Cancer biology MSc courses and Postgraduate awards. 2010- 2015: Member of the trust resuscitation committee and am senior member on the local ethics committee. Founder member and board for MLSRF charity (Chair- Sir Paul Nurse). Founder member and advisory board for the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM). In 2011 and 2014, Organiser, scientific committee member and local host for HEART UK. Grant reviewer and research analyst Extensive experience reviewing large multi-million euro grants for the EC; Marie Curie, ITNs, STREPS, NoEs, IPs, from FP5 through to Horizon 2020. Also for the BBSRC, EPSRC and MRC in the UK. Also grants aimed specifically at private sector funding, including Eurostars. Experience in applying for Innovate UK grants. Acted as advisor on infrastructure funding to the Government of Cyprus on behalf of the EC. Frequent reviewer for scientific journals.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Kovacheva, V. N., Khan, Adnan M., Khan, Michael, Epstein, David B. A., Rajpoot, Nasir M. (Nasir Mahmood). 2014. DiSWOP : a novel measure for cell-level protein network analysis in localized proteomics image data. Bioinformatics, Volume 30 (Number 3), pp. 420-427, View Khan, Michael, Taibjee, S. M., Poole, C. J., Gach, J. E.. 2014. Bullous reaction at docetaxel infusion site. Clinical and Experimental Dermatology, Volume 39 (Number 1), pp. 58-60, View Khan, Adnan M., Raza, Shan-e-Ahmed, Khan, Michael, Rajpoot, Nasir M.. 2014. Cell phenotyping in multi-tag fluorescent bioimages. Neurocomputing, Volume 134, pp. 254-261, View Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, Michael, Drevs, J.. 2014. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. Journal of Clinical Oncology, 32 (36), pp. 4141-4148, View Raza, Shan-e-Ahmed, Humayun, Ahmad, Abouna, Sylvie, Nattkemper, Tim W., Epstein, David B. A., Khan, Michael, Rajpoot, Nasir M. (Nasir Mahmood). 2012. RAMTaB : robust alignment of multi-tag bioimages. PLoS One, Vol.7 (No.2), View Kuse, Manohar, Wang, Yi-Fang, Kalasannavar, V, Khan, Michael, Rajpoot, Nasir M. (Nasir Mahmood). 2012. Local isotropic phase symmetry measure for detection of beta cells and lymphocytes. Journal of Pathology Informatics, Vol.2 (No.2), View Tarabra, Elena, Pelengaris, Stella, Khan, Michael. 2012. A simple matter of life and death : the trials of postnatal beta-cell mass regulation. International Journal of Endocrinology, Vol.2012, View Hattersley, John G., Möhlig, Matthias, Roden, Michael, Dr., Arafat, Ayman M., Loeffelholz, Christian von, Nowotny, Peter, Machann, Jürgen, Hierholzer, Johannes, Osterhoff, Martin, Khan, Michael, Pfeiffer, Andreas F. H., Weickert, Martin O.. 2012. Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques. PLoS ONE, Vol.7 (No.6), View Kolling, J., Langenkamper, D., Abouna, S., Khan, Michael, Nattkemper, Tim W.. 2012. WHIDE--a web tool for visual data mining colocation patterns in multivariate bioimages. Bioinformatics, Vol.28 (No.8), pp. 1143-1150, View